In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
Publication of a systematic review and meta-analysis on the efficacy of gelatin tannate in acute diarrhea in children.
Aim: To investigate by meta-analysis the efficacy of gelatin tannate (GT), a mucosal barrier protector, in children with acute gastroenteritis.
Conclusion: GT significantly (p < 0.01) reduced stool frequency at 12 h as well as the number of patients with diarrhea or liquid stools at 24 h (p < 0.01), compared with placebo.
No adverse events were reported in any of the RCTs analyzed. The unique mechanism and lack of systemic absorption of GT make this device an interesting addition to the current armamentarium for treating acute gastroenteritis in children.
Adiarin® is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia.
Tasectan® in Europe is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Novinthetical Pharma SA). In Russia, Adiarin® has been granted local marketing authorization as class II medical device.
